MiniMed 670G System
Medtronic MiniMed, Inc. · Decision date Sep 28, 2016
What did the FDA approve?
The September 28, 2016 approval covers the Medtronic MiniMed 670G System, an automated insulin dosing device system with single hormonal control. The system delivers basal insulin at user-selectable rates and insulin boluses in user-selectable amounts for managing Type 1 diabetes in persons fourteen and older requiring insulin. It also continuously monitors and trends glucose levels in fluid under the skin. SmartGuard technology can be programmed to automatically adjust basal insulin delivery based on sensor glucose values and to suspend delivery when sensor glucose falls below or is predicted to fall below predefined thresholds.
The system consists of the MiniMed 670G insulin pump, Guardian Link (3) Transmitter, Guardian Sensor (3), One-Press Serter, and Contour NEXT Link 2.4 Glucose Meter. The Guardian Sensor (3) is indicated for 7 days of continuous use and is adjunctive, not a replacement for standard blood glucose monitoring. The statement reports intended uses; it does not independently establish safety or clinical effectiveness. The source does not describe clinical trial data or comparative outcomes.
FDA approval order statement
MiniMed 670G SystemThe Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of Type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G System includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values.The Medtronic MiniMed 670G System consists of the following devices: MiniMed 670G insulin pump, the Guardian Link (3) Transmitter, the Guardian Sensor (3), One-Press Serter, and the Contour NEXT Link 2.4 Glucose Meter. The system requires a prescription.The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a finger stick may be required. All therapy adjustments should be based on measurements obtained using a home glucose monitor and not on values provided by the Guardian Sensor (3).Guardian Sensor (3)The Guardian Sensor (3) is intended for use with the MiniMed 670G system to continuously monitor glucose levels in persons with diabetes. It is intended to be used for detecting trends and tracking patterns in persons aged fourteen years and older, and to be used by the MiniMed 670G system to automatically adjust basal insulin levels. It is indicated for use as an adjunctive device to complement, not replace, information obtained from standard blood glucose monitoring devices. The sensor is intended for single use and requires a prescription. The Guardian Sensor (3) is indicated for 7 days of continuous use.One-press SerterThe One-press Serter is used as an aid for inserting the sensor. It is indicated for single-patient use and it is not intended for multiple-patient use.Guardian Link (3) Transmitter The Guardian Link (3) Transmitter is intended for use with the MiniMed 670G System. The Guardian Link (3) Transmitter powers the glucose sensor, collects and calculates sensor data, and wirelessly sends the data to the MiniMed 670G insulin pump. The Transmitter is intended for single-patient multi-use. Contour NEXT Link 2.4 Glucose MeterThe Contour Next Link 2.4 Wireless Blood Glucose Monitoring System is an over the counter (OTC) device utilized by persons with diabetes in home settings for the measurement of glucose in whole blood, and is for single patient use only and should not be shared. The Contour Next Link 2.4 wireless blood glucose monitoring system is indicated for use with fresh capillary whole blood samples drawn from the fingertip and palm only. The Contour NEXT Test Strips are intended for self-testing by persons with diabetes for the quantitative measurement of glucose in whole blood samples from 20 to 600 mg/dL. The Contour Next Link 2.4 wireless blood glucose monitoring system is intended to be used to transmit glucose values to the MiniMed 670G pump and facilitate transfer of information to Medtronic CareLink Software through the use of radio frequency communication. The Contour Next Link 2.4 Wireless Blood Glucose Monitoring System is not intended for the diagnosis of, or screening for, diabetes mellitus. It is not intended for use on neonates.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Clinical Chemistry
- Decision date
- Sep 28, 2016
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P160017
- Regulatory pathway
- Premarket approval application
- Applicant
- Medtronic MiniMed, Inc.
- Product code
- OZP
- Decision code
- APPR
- Decision date
- Sep 28, 2016
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Automated insulin dosing device system, single hormonal control.
- Applicant
- Medtronic MiniMed, Inc.
- Product code
- OZP
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P160017 received
Application receipt date recorded by FDA.
P160017 · FDA decision
APPR
P160017/S140 · Related supplement
MiniMed 780G System
Timeline entries are records held by MedtechLedger for P160017. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P160017
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MiniMed 780G SystemP160017/S140 | Medtronic MiniMed, Inc. | PMA supplement | Sep 29, 2026 | FDA |
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Medtronic MiniMed, Inc.
- Headquarters
- Not reported
- Brand website
- medtronic.com
- FDA applicant address
- 18000 Devonshire St., Northridge, CA, 91325
Sources and methodology
- Original FDA record: P160017
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records